Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

venous thromboembolism

Bayer symbol

Bayer’s non-hormonal menopause drug elinzanetant shows promise in long-term study

Vasomotor symptoms are reported by up to 80% of women during the menopausal transition

Bayer symbol

Bayer and BridgeBio enter European partnership worth up to $310m for ATTR-CM

The rare and progressive condition affects around 500,000 people worldwide

- PMLiVE

Janssen’s Carvykti recommended by CHMP for earlier multiple myeloma treatment

The blood cancer affects approximately 160,000 people worldwide

Bayer symbol

Bayer’s non-hormonal menopause drug elinzanetant shows promise in phase 3 studies

Vasomotor symptoms are estimated to affect up to 80% of menopausal women

- PMLiVE

Janssen reveals positive results for nipocalimab in rheumatoid arthritis

About 13 million people worldwide are affected by the chronic inflammatory disease

Bayer symbol

Bayer and BlueRock announce positive results from Parkinson’s cell therapy trial

Phase 1 results suggest the stem cell-based treatment improves symptoms of the condition

- PMLiVE

Janssen’s Tecvayli approved by EC for reduced dosing frequency in multiple myeloma

Tecvayli was the first BCMA-targeting bispecific antibody to be approved in Europe

- PMLiVE

Janssen’s Talvey granted FDA accelerated approval for difficult-to-treat blood cancer

The therapy showed an overall response rate of more than 70% in a broad range of patients

- PMLiVE

Janssen receives positive CHMP opinion for Talvey in multiple myeloma

More than 50,900 people in Europe were diagnosed with multiple myeloma in 2020

- PMLiVE

Johnson & Johnson sues US government over Medicare drug price negotiation programme

The IRA allows Medicare to negotiate lower prices for a selected group of medicines

- PMLiVE

Alliance for Genomic Discovery announces its five founding biopharma members

The AGD aims to accelerate drug development and expand the diversity of genomic data

- PMLiVE

Janssen signs $2.5bn deal with Nanobiotix for late-stage radiotherapy enhancer

The agreement marks a significant boost to the Johnson & Johnson unit’s oncology pipeline

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links